This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Response to Ranibizumab in Polypoidal Choroidal Vasculopathy (PCV)and SNPs

This study has been completed.
Information provided by:
Nihon University Identifier:
First received: January 5, 2011
Last updated: NA
Last verified: January 2011
History: No changes posted
To determine whether complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2) genotypes have a pharmacogenetic effect on the treatment of polypoidal choroidal vasculopathy (PCV) with ranibizumab.

Polypoidal Choroidal Vasculopathy

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Association of Complement Factor H and ARMS2 Genotypes With Response of Polypoidal Choroidal Vasculopathy to Intravitreal Ranibizumab

Resource links provided by NLM:

Further study details as provided by Nihon University:

Primary Outcome Measures:
  • Association of Complement Factor H and ARMS2 Genotypes with Response of Polypoidal Choroidal Vasuculopathy to Intravitral Ranibizumab [ Time Frame: a month after injection ]

Biospecimen Retention:   Samples With DNA
white blood cell

Enrollment: 74
Study Start Date: April 2008
Study Completion Date: March 2010
Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   50 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
outpatients in hospital

Inclusion Criteria:

  • Clinical diagnosis of Polypoidal choroidal vasculopathy
  • must have injection of Ranibizumab

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01271426

Surugadai Nihon university hospital
1-8-13 Kandasurugadai Chiyoda-ku, Tokyo, Japan, 101-8309
Sponsors and Collaborators
Nihon University
  More Information Identifier: NCT01271426     History of Changes
Other Study ID Numbers: NihonU-1
Study First Received: January 5, 2011
Last Updated: January 5, 2011

Keywords provided by Nihon University:
Polypoidal Choroidal Vasculopathy

Additional relevant MeSH terms:
Vascular Diseases
Cardiovascular Diseases
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents processed this record on September 21, 2017